DEFA14A: Jaguar Health Amends Proxy Statement on Broker Voting

Sentiment:

Proxy Statement Supplement 6 August 2025 8:31 PM

Jaguar Health, Inc. has issued a supplement to its definitive proxy statement, clarifying that Proposal 7 for its 2025 Annual Meeting is a non-routine matter under NYSE rules, impacting broker voting.

Capital raiseProposal 3 seeks to approve an amendment to the 2014 Stock Incentive Plan to increase the number of shares of Common Stock authorized for issuance by 307,670 shares.Proposal 4 seeks to approve the issuance of Common Stock issuable upon exchange of shares of Series L Preferred Stock to certain accredited investors.Proposal 5 seeks to approve the issuance of Common Stock issuable upon exchange of shares of Series M Preferred Stock to certain accredited investors.Proposal 6 seeks to approve the issuance of up to an aggregate of 1,409,732 shares of Common Stock upon conversion of certain 6% convertible promissory notes and exercise of related warrants.

Summary

A supplement to the definitive proxy statement dated July 21, 2025, has been filed for the 2025 Annual Meeting of Stockholders scheduled for August 19, 2025.
Proposal 7, which seeks discretionary authority to adjourn the Annual Meeting to solicit additional proxies for Proposals 3, 4, 5, and 6, is now classified as a non-routine matter under New York Stock Exchange (NYSE) rules.
Brokerage firms are prohibited from voting uninstructed shares on non-routine matters, including Proposal 7.
The disclosures under the 'Broker Voting' section in the original Proxy Statement have been amended and restated to reflect this clarification.
Proposal 2, concerning the ratification of RBSM as the independent registered public accounting firm for fiscal year ending December 31, 2025, remains a routine matter.
Proposals 1 (elect Class I directors), 3 (amend 2014 Stock Incentive Plan), 4 (approve issuance of Common Stock for Series L Preferred Stock exchange), 5 (approve issuance of Common Stock for Series M Preferred Stock exchange), and 6 (approve issuance of Common Stock for convertible notes and warrants) are confirmed as non-routine matters.

Sentiment

Score: 5

Explanation: The filing is a procedural supplement clarifying proxy voting rules, with no direct impact on the company's financial performance or operational outlook.

Risks

There is a risk that Proposals 3, 4, 5, and 6 may not receive sufficient votes for approval if Proposal 7 (adjournment authority) fails to pass, especially given its reclassification as a non-routine matter requiring explicit stockholder instructions for broker votes.

Future Outlook

The filing does not provide forward-looking statements regarding the company's operational performance or financial guidance, focusing solely on procedural aspects of the upcoming Annual Meeting.

Industry Context

This filing is a standard procedural update common in corporate governance, clarifying voting mechanics for an upcoming annual meeting. It does not provide insights into broader industry trends or competitive landscape.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Clarification of Broker Voting Rules	The proxy statement has been amended to clarify that Proposal 7 (discretionary authority to adjourn the Annual Meeting) is a non-routine matter under NYSE rules, meaning brokers cannot vote uninstructed shares on this proposal.	From the date of this Supplement	Requires beneficial owners to provide explicit voting instructions for non-routine matters, including Proposal 7, potentially impacting the approval rate or quorum if instructions are not received.

Stakeholder Impact

Shareholders: Must be aware of the updated broker voting rules, particularly for non-routine matters, to ensure their votes are cast as intended.
Brokerage Firms: Receive clarified guidance on their discretionary voting authority for specific proposals.

Next Steps

The 2025 Annual Meeting of Stockholders is scheduled for August 19, 2025.
Stockholders are advised to provide timely voting instructions to their brokers for all non-routine matters to ensure their votes are counted.

Key Dates

Date	Description
June 24, 2025	Date of note exchange and warrant purchase agreements related to Proposal 6.
July 21, 2025	Date of the original Definitive Proxy Statement.
August 19, 2025	Date of the 2025 Annual Meeting of Stockholders.

Recommendation

hold

The filing is a procedural supplement to a proxy statement, clarifying broker voting rules for the upcoming annual meeting. It does not contain new financial results, operational updates, or strategic shifts that would alter the fundamental investment thesis for Jaguar Health. While some proposals relate to equity issuance, the details and implications of these are part of the original proxy, and this supplement merely addresses voting mechanics. Therefore, a 'hold' recommendation is appropriate as there's no new information to justify a change in position.

Keywords

Jaguar Health, SEC filing, proxy statement, annual meeting, broker voting, corporate governance, stock incentive plan, preferred stock, convertible notes, warrants, NYSE rules

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.